COEP
Coeptis Therapeutics Holdings Inc
Price Chart
No historical data available
Latest Quote
$16.40
Current Price| Open | $16.23 |
| Day High | $17.27 |
| Day Low | $15.87 |
| Volume | 111,929 |
Stock Information
| Shares Outstanding | 6.22M |
| Total Debt | $269K |
| Cash Equivalents | $6.35M |
| Revenue | $1.36M |
| Net Income | $-11.92M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $102.06M |
| EPS (TTM) | $-2.81 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $96.48M |
| Sales | $1.36M |
| Income | $-11.92M |
| Book/sh | $2.36 |
| Cash/sh | $1.02 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 3.60 |
| Current Ratio | 4.16 |
| Debt/Eq | 1.91 |
Returns & Margins
| ROA | -65.05% |
| ROE | -136.91% |
| Gross Margin | 86.75% |
| Operating Margin | -230.65% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| Forward P/E | -96.47 |
| P/S | 74.88 |
| P/B | 6.95 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $12.88 |
| SMA50 | $12.25 |
| SMA200 | $13.58 |
| RSI | 74.20 |
| ATR | 1.1743 |
| Shares Float | 5.25M |
| Short Float | 8.00% |
| Short Ratio | 10.53 |
| Volatility | -0.43 |
| Rel Volume | 1.87 |
Performance History
| Week | +11.95% |
| Month | +46.56% |
| Quarter | +17.14% |
| 6 Months | +9.37% |
| YTD | +12.02% |
| Year | +42.61% |
| 3 Years | -42.25% |
| 10 Years | -87.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About Coeptis Therapeutics Holdings Inc
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $180,625 | $0 | $0 | $0 |
| Cost Of Revenue | $180,625 | $0 | $0 | $0 |
| Total Revenue | $1,363,045 | $0 | $0 | $0 |
| Operating Revenue | $1,363,045 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $642,379 | $462,305 | $107,685 | $218,412 |
| Total Expenses | $14,406,543 | $10,054,488 | $21,491,125 | $34,195,964 |
| Other Income Expense | $1,292,190 | $-595,361 | $332,273 | $-3,159,841 |
| Other Non Operating Income Expenses | $122,004 | $-16,444 | $-235,477 | $233,701 |
| Net Non Operating Interest Income Expense | $-525,884 | $-227,563 | $-107,685 | $-218,412 |
| Interest Expense Non Operating | $642,379 | $462,305 | $107,685 | $218,412 |
| Operating Expense | $14,225,918 | $10,054,488 | $21,491,125 | $34,195,964 |
| Selling And Marketing Expense | $105,000 | $0 | $12,710 | $8,331 |
| General And Administrative Expense | $11,843,768 | $6,722,940 | $13,822,881 | $34,166,746 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,917,015 | $-10,680,452 | $-21,266,537 | $-37,574,217 |
| Net Interest Income | $-525,884 | $-227,563 | $-107,685 | $-218,412 |
| Interest Income | $116,495 | $234,742 | - | - |
| Normalized Income | $-13,087,201 | $-10,101,535 | $-21,834,287 | $-34,180,675 |
| Net Income From Continuing And Discontinued Operation | $-11,917,015 | $-10,680,452 | $-21,266,537 | $-37,574,217 |
| Total Operating Income As Reported | $-13,043,498 | $-10,054,488 | $-21,491,125 | $-34,195,964 |
| Net Income Common Stockholders | $-11,917,015 | $-10,680,452 | $-21,266,537 | $-37,574,217 |
| Net Income | $-11,917,015 | $-10,680,452 | $-21,266,537 | $-37,574,217 |
| Net Income Including Noncontrolling Interests | $-12,277,192 | $-10,877,412 | $-21,266,537 | $-37,574,217 |
| Net Income Continuous Operations | $-12,277,192 | $-10,877,412 | $-21,266,537 | $-37,574,217 |
| Pretax Income | $-12,277,192 | $-10,877,412 | $-21,266,537 | $-37,574,217 |
| Special Income Charges | $159,035 | $-237,257 | $0 | $-3,393,542 |
| Interest Income Non Operating | $116,495 | $234,742 | - | - |
| Operating Income | $-13,043,498 | $-10,054,488 | $-21,491,125 | $-34,195,964 |
| Depreciation Amortization Depletion Income Statement | $1,000,000 | $1,000,000 | $1,000,000 | - |
| Depreciation And Amortization In Income Statement | $1,000,000 | $1,000,000 | $1,000,000 | - |
| Amortization Of Intangibles Income Statement | $1,000,000 | $1,000,000 | $1,000,000 | - |
| Gross Profit | $1,182,420 | $0 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | - | $-5.56 | $-16.56 | $-52.60 |
| Basic EPS | - | $-5.56 | $-16.56 | $-52.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,582,402 | $-8,797,557 | $-20,690,813 | $-32,960,879 |
| Total Unusual Items | $1,170,186 | $-578,917 | $567,750 | $-3,393,542 |
| Total Unusual Items Excluding Goodwill | $1,170,186 | $-578,917 | $567,750 | $-3,393,542 |
| Reconciled Depreciation | $1,222,597 | $1,038,633 | $1,035,789 | $1,001,384 |
| EBITDA (Bullshit earnings) | $-10,412,216 | $-9,376,474 | $-20,123,063 | $-36,354,421 |
| EBIT | $-11,634,813 | $-10,415,107 | $-21,158,852 | $-37,355,805 |
| Diluted NI Availto Com Stockholders | $-11,917,015 | $-10,680,452 | $-21,266,537 | $-37,574,217 |
| Minority Interests | $360,177 | $196,960 | $0 | - |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | $-159,035 | $200,000 | - | $3,393,542 |
| Write Off | $0 | $37,257 | $0 | $0 |
| Gain On Sale Of Security | $1,011,151 | $-341,660 | $567,750 | - |
| Amortization | $1,000,000 | $1,000,000 | $1,000,000 | - |
| Research And Development | $1,277,150 | $2,331,548 | $6,668,244 | $20,887 |
| Selling General And Administration | $11,948,768 | $6,722,940 | $13,822,881 | $34,175,077 |
| Other Gand A | $8,940,104 | $3,895,912 | $11,891,083 | $34,166,746 |
| Salaries And Wages | $2,903,664 | $2,827,028 | $1,931,798 | - |
| Diluted Average Shares | - | $1,924,639 | $1,284,499 | $714,783 |
| Basic Average Shares | - | $1,924,639 | $1,284,499 | $714,783 |
Fetched: 2026-04-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $12,646,577 | $2,840,249 | $813,964 | $4,453,329 |
| Total Assets | $16,153,921 | $8,908,660 | $4,571,089 | $7,915,689 |
| Total Non Current Assets | $8,803,772 | $7,857,368 | $2,821,376 | $3,973,956 |
| Goodwill And Other Intangible Assets | $915,417 | $541,875 | $0 | - |
| Other Intangible Assets | $915,417 | $541,875 | - | - |
| Current Assets | $7,350,149 | $1,051,292 | $1,749,713 | $3,941,733 |
| Prepaid Assets | $991,903 | $518,407 | $241,601 | $142,356 |
| Receivables | $7,348 | $0 | $38,978 | $8,075 |
| Accrued Interest Receivable | $7,348 | $0 | $38,978 | $0 |
| Cash Cash Equivalents And Short Term Investments | $6,350,898 | $532,885 | $1,469,134 | $3,791,302 |
| Cash And Cash Equivalents | $5,674,302 | $532,885 | $1,469,134 | $3,791,302 |
| Cash Financial | $5,674,302 | $532,885 | $1,469,134 | $3,791,302 |
| Other Non Current Assets | - | $1,554,166 | $2,554,166 | $3,554,167 |
| Non Current Prepaid Assets | - | $0 | $158,333 | $348,333 |
| Notes Receivable | - | - | $3,500,000 | $0 |
| Accounts Receivable | - | - | $0 | $8,075 |
| Inventory | - | - | - | - |
| Debt | ||||
| Total Debt | $268,875 | $1,399,053 | $1,224,226 | $2,056,341 |
| Long Term Debt And Capital Lease Obligation | $150,000 | $168,875 | $211,179 | $164,723 |
| Long Term Debt | $150,000 | $150,000 | $150,000 | $150,000 |
| Current Debt And Capital Lease Obligation | $118,875 | $1,230,178 | $1,013,047 | $1,891,618 |
| Current Debt | $100,000 | $1,187,873 | $975,000 | $1,850,000 |
| Other Current Borrowings | $100,000 | $1,187,873 | $975,000 | $1,850,000 |
| Net Debt | - | $804,988 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,085,764 | $5,041,434 | $3,757,125 | $3,462,360 |
| Total Non Current Liabilities Net Minority Interest | $317,625 | $528,125 | $768,429 | $1,289,723 |
| Derivative Product Liabilities | $167,625 | $359,250 | $557,250 | $1,125,000 |
| Current Liabilities | $1,768,139 | $4,513,309 | $2,988,696 | $2,172,637 |
| Other Current Liabilities | $120,000 | $1,276,484 | - | - |
| Current Deferred Liabilities | $599,455 | $0 | - | - |
| Payables And Accrued Expenses | $929,809 | $2,006,647 | $1,975,649 | $281,019 |
| Payables | $888,755 | $1,269,763 | $1,419,699 | $99,021 |
| Accounts Payable | $888,755 | $1,269,763 | $1,419,699 | $99,021 |
| Current Notes Payable | - | $1,087,873 | $875,000 | - |
| Equity | ||||
| Common Stock Equity | $13,561,994 | $3,382,122 | $813,964 | $4,453,329 |
| Total Equity Gross Minority Interest | $14,068,157 | $3,867,226 | $813,964 | $4,453,329 |
| Stockholders Equity | $13,561,994 | $3,382,124 | $813,964 | $4,453,329 |
| Other Equity Interest | $-3,686,544 | $-1,558,125 | $-3,500,000 | - |
| Retained Earnings | $-109,953,728 | $-98,036,713 | $-87,356,260 | $-66,089,723 |
| Preferred Stock Equity | - | $2 | - | - |
| Other | ||||
| Ordinary Shares Number | $5,746,948 | $2,116,191 | $1,766,551 | $978,341 |
| Share Issued | $5,746,948 | $2,116,191 | $1,766,551 | $978,341 |
| Tangible Book Value | $12,646,577 | $2,840,247 | $813,964 | $4,453,329 |
| Invested Capital | $13,811,994 | $4,719,995 | $1,938,964 | $6,453,329 |
| Working Capital | $5,582,010 | $-3,462,017 | $-1,238,983 | $1,769,096 |
| Capital Lease Obligations | $18,875 | $61,180 | $99,226 | $56,341 |
| Total Capitalization | $13,711,994 | $3,532,124 | $963,964 | $4,603,329 |
| Minority Interest | $506,163 | $485,102 | $0 | - |
| Additional Paid In Capital | $127,201,691 | $102,976,748 | $91,670,045 | $70,541,095 |
| Capital Stock | $575 | $214 | $179 | $1,957 |
| Common Stock | $575 | $212 | $179 | $1,957 |
| Preferred Stock | $0 | $2 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $18,875 | $61,179 | $14,723 |
| Current Deferred Revenue | $599,455 | $0 | - | - |
| Current Capital Lease Obligation | $18,875 | $42,305 | $38,047 | $41,618 |
| Current Accrued Expenses | $41,054 | $736,884 | $555,950 | $181,998 |
| Investments And Advances | $7,860,083 | $5,691,084 | $0 | - |
| Net PPE | $28,272 | $70,243 | $108,877 | $71,456 |
| Accumulated Depreciation | $-225,151 | $-183,767 | $-13,931 | $-12,695 |
| Gross PPE | $253,423 | $254,010 | $122,808 | $84,151 |
| Machinery Furniture Equipment | $9,873 | $10,460 | $25,237 | $25,237 |
| Buildings And Improvements | $243,550 | $243,550 | - | - |
| Properties | $0 | $0 | - | - |
| Other Short Term Investments | $676,596 | $0 | - | - |
| Other Properties | - | $59,783 | $97,571 | $58,914 |
| Treasury Stock | - | - | $0 | $0 |
Fetched: 2026-04-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,603,036 | $-6,649,281 | $-7,239,514 | $-3,875,811 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,603,036 | $-6,649,281 | $-7,239,514 | $-3,875,811 |
| Cash Flow From Continuing Operating Activities | $-8,603,036 | $-6,649,281 | $-7,239,514 | $-3,875,811 |
| Operating Gains Losses | $-432,795 | $549,810 | $2,045,433 | $28,263,857 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $0 | $0 |
| Cash Flow From Continuing Investing Activities | - | - | - | $0 |
| Capital Expenditure | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $12,972,303 | $4,014,001 | $5,292,346 | $3,271,486 |
| Financing Cash Flow | $13,744,453 | $5,713,032 | $4,917,346 | $5,487,555 |
| Cash Flow From Continuing Financing Activities | $13,744,453 | $5,713,032 | $4,917,346 | $5,487,555 |
| Net Preferred Stock Issuance | $5,455,000 | $3,914,001 | $0 | - |
| Preferred Stock Issuance | $5,455,000 | $3,914,001 | $0 | - |
| Net Common Stock Issuance | $7,517,303 | $100,000 | $5,292,346 | $3,271,486 |
| Common Stock Issuance | $7,517,303 | $100,000 | $5,292,346 | $3,271,486 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Net Other Financing Charges | - | - | - | $-614,580 |
| Other | ||||
| Repayment Of Debt | $-218,750 | $-650,969 | $-1,225,000 | $-2,417,000 |
| Issuance Of Debt | $990,000 | $1,850,000 | $650,000 | $0 |
| Interest Paid Supplemental Data | $8,772 | $8,772 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $5,674,302 | $532,885 | $1,469,134 | $3,791,302 |
| Beginning Cash Position | $532,885 | $1,469,134 | $3,791,302 | $2,179,558 |
| Changes In Cash | $5,141,417 | $-936,249 | $-2,322,168 | $1,611,744 |
| Proceeds From Stock Option Exercised | $900 | $500,000 | $200,000 | $5,247,649 |
| Net Issuance Payments Of Debt | $771,250 | $1,199,031 | $-575,000 | $-2,417,000 |
| Net Long Term Debt Issuance | $771,250 | $1,199,031 | $-575,000 | $-2,417,000 |
| Long Term Debt Payments | $-218,750 | $-650,969 | $-1,225,000 | $-2,417,000 |
| Long Term Debt Issuance | $990,000 | $1,850,000 | $650,000 | $0 |
| Change In Working Capital | $-1,460,052 | $-125,262 | $1,727,083 | $-550,335 |
| Change In Other Current Liabilities | $-157,306 | $196,953 | $-30,324 | - |
| Change In Payables And Accrued Expense | $-821,901 | $30,999 | $1,697,555 | $-52,199 |
| Change In Accrued Expense | $-440,889 | $180,934 | $376,878 | $-17,128 |
| Change In Payable | $-381,012 | $-149,935 | $1,320,677 | $-35,071 |
| Change In Account Payable | $-381,012 | $-149,935 | $1,320,677 | $-35,071 |
| Change In Prepaid Assets | $-473,497 | $-118,472 | $90,755 | $-490,689 |
| Change In Receivables | $-7,348 | $-234,742 | $-30,903 | $-8,075 |
| Other Non Cash Items | $3,041,810 | $1,659,972 | $8,741,215 | $4,983,500 |
| Stock Based Compensation | $1,215,692 | $1,104,978 | $477,503 | $0 |
| Unrealized Gain Loss On Investment Securities | $86,904 | $0 | - | - |
| Depreciation Amortization Depletion | $1,222,597 | $1,038,633 | $1,035,789 | $1,001,384 |
| Depreciation And Amortization | $1,222,597 | $1,038,633 | $1,035,789 | $1,001,384 |
| Depreciation | $1,222,597 | $1,038,633 | $1,035,789 | - |
| Gain Loss On Investment Securities | $-273,760 | $349,810 | $2,045,433 | $28,263,857 |
| Net Income From Continuing Operations | $-12,277,192 | $-10,877,412 | $-21,266,537 | $-37,574,217 |
| Changes In Account Receivables | - | $0 | $8,075 | $-8,075 |
| Change In Other Working Capital | - | - | $4,228 | $628 |
| Common Stock Payments | - | - | - | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
| Net PPE Purchase And Sale | - | - | - | - |
| Purchase Of PPE | - | - | - | - |
| Change In Inventory | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
Fetched: 2026-04-26